The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Treosulfan versus busulfan-based conditioning for HSCT in transfusion-dependent thalassemia
Rita Beier, MD, Hannover Medical School, Hannover, Germany, summarizes the results of a retrospective analysis evaluating the impact of treosulfan versus busulfan-based conditioning regimens in hematopoietic stem cell transplantation (HSCT) for patients with transfusion-dependent thalassemia (TDT). Interestingly, results demonstrated that the CD3+ T-cell count has a significant impact on graft success after HSCT in patients with TDT. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
